Abstract:BackgroundEssential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential medicines. Research about the initiation of National Essential Medicines Policy in Chinese secondary and tertiary hospitals is inadequate, and the long-term effect on access after the reform is still unknown. This study's objective was to investigate the access to essential medicines in mainland China's secondary and tertiary hospitals.MethodsData on the access to 30 essential medicines from China's National Essential Medicine List were obtained from China Medicine Economic Information database covering 396 secondary hospitals and 763 tertiary hospitals. We improved the standard methodology developed by the World Health Organization and the Health Action International to measure the availability, median price ratio (MPR) and the incidence of catastrophic drug expenditure (CDE).ResultsFive essential medicines had >50% availability and the nationwide availability kept steady; availability of drugs in eastern regions of China was significantly higher than the central and western regions. The median MPR of 30 drugs nationwide kept steady approximately 5; MPR of drugs in the eastern regions was significantly higher than the central and western regions and the ratio of MPR of innovator brands to generics increased from 3.66 to 6.32 during the study period. The incidence of CDE caused by essential medicines decreased from 2011 to 2014; brand name medicines were more likely to cause CDE than generics and rural patients have a greater tendency to fall into CDE.ConclusionsAfter the implementation of National Essential Medicines Policy, the MPR of essential medicines was well controlled and became more affordable in the context of steady availability. This has highlighted the problems associated with region disparity and inequity between rural and urban areas in the delivery of essential medicines and sustainable mechanisms are needed to deepen the National Essential Medicines Policy in mainland China.

Study on Prices and Availability of 47 Kinds of Drugs in Shaanxi Province

Analysis on the Impacts of the Essential Medicines System on Primary Health Institutions in Shaanxi Province: Based on a Sample Survey of 4 Primary Health Institutions in 2 Counties

Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study

International Comparison of Drug Price Level in China

Comparative analysis on the price of essential medicines:Based on the sample survey of primary health care institutions and pharmacies in 18 provinces

Comparison of the Retail Drug Prices between China and Other Developed Countries or Districts

An evidence-base study on drug price in Shanghai

Empirical Research of Price Difference and Market Share Between Brand-Name Drugs and Generics in One Province in China

Empirical Study on Essential Medicine Price in China

Empirical research on the price level of drugs for non-communicable diseases in basic drug list of Shanghai Qingpu District

Access to anticancer medicines in public hospitals of Northwestern China

Short-term differences in drug prices after implementation of the national essential medicines system: A case study in rural Jiangxi Province, China

Analysis of Selecting Low-cost Medicine Lists in 31 Provinces(Autonomous Regions or Municipalities)of Chi-na

Empirical Study on the Availability of Essential Medicines in Public Health and Medical Institutions of Shang-hai Qingpu District

Empirical Study on Availability of Essential Medicine in China

Comparative Study on the Policies of Drug Price and Expenditure Control in China and Other Countries

Impact on Hospital Medicine After Adjusting the Drug Pricing Method

A Survey of Availability, Price and Affordability of Essential Medicines from 2011 to 2016 in Chinese Secondary and Tertiary Hospitals

Demand analysis of drugs outside the list of national essential medicines and Shanghai supplementary drugs in the community health centers of Shanghai

Medicine Use and Cost Analysis by Prescriptions of Community Health Service Institutions in Chengdu and Shenyang

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China